These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 28182323)

  • 1. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
    Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
    J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
    Aguilar C
    Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
    Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
    Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
    Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
    Jones JA; Hillmen P; Coutre S; Tam C; Furman RR; Barr PM; Schuster SJ; Kipps TJ; Flinn IW; Jaeger U; Burger JA; Cheng M; Ninomoto J; James DF; Byrd JC; O'Brien SM
    Br J Haematol; 2017 Jul; 178(2):286-291. PubMed ID: 28397242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Major Bleeding with Ibrutinib.
    Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
    Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
    Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibrutinib Inhibits Platelet Integrin αIIbβ3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
    Bye AP; Unsworth AJ; Vaiyapuri S; Stainer AR; Fry MJ; Gibbins JM
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2326-35. PubMed ID: 26359510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
    Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
    Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
    Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
    Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
    Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
    Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
    Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
    Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
    Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
    Tobinai K; Ogura M; Ishizawa K; Suzuki T; Munakata W; Uchida T; Aoki T; Morishita T; Ushijima Y; Takahara S
    Int J Hematol; 2016 Jan; 103(1):86-94. PubMed ID: 26588924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.